Skip to main content

Table 1 The primary characteristics of the selected studies

From: Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

First author Treatment No. of patients No. of treatment-related toxicities grade ≥ 3
    Total Hepatotoxicity Neutropenia Dyspnoea Fatigue Vomiting Diarrhoea Nausea Constipation Amylase increased Elevated lipase
D.W. Kim [10] Crizotinib 136 27 5 3 4 NA NA NA NA NA NA NA
Camidge, D. R. [11] Crizotinib 149 36 6 9 1 2 1 0 1 1 0 0
Perol, M. [12] Crizotinib 187 NA 5 NA NA NA NA NA NA NA NA NA
Shaw, Alice T. [13] Crizotinib 172 57 27 23 7 4 2 0 2 4 NA NA
Cao, Y. [14] Crizotinib 40 6 4 0 0 0 2 0 0 0 0 0
Hernandez, Berta [15] Crizotinib 10 NA 2 NA NA NA NA NA NA NA NA NA
Shaw, A. T. [3] Ceritinib 81 46 19 NA NA 5 5 6 6 NA 8 8
Solomon, B. J. [16] Crizotinib 171 NA 24 19 5 5 3 4 2 3 NA NA
Chaigneau, A. [4] Ceritinib 10 2 1 0 0 0 0 0 0 0 0 0
Cui, S. [17] Crizotinib 72 10 3 0 0 0 5 0 0 0 0 0
Felip, E. [5] Ceritinib 124 NA 17 NA NA NA NA NA NA NA NA NA
Mok, T. [6] Ceritinib 140 64 22 NA NA NA 6 9 8 NA NA NA
Cui, S. [18] Crizotinib 56 8 2 0 0 0 5 0 0 0 0 0
Kim, D. W. [7] Ceritinib 246 125 73 0 10 12 11 15 15 0 8 16
Ou, Sai-Hong [8] Alectinib 138 38 2 NA 4 1 1 1 0 0 NA NA
Shaw, A. T. [9] Alectinib 87 35 5 1 3 0 0 0 0 0 0 0
Zhang, Q. [19] Crizotinib 7 1 1 0 0 0 0 0 0 0 0 0
  1. NA not available